Georgia Medicare Cardiovascular Screening (2026 Guide)

title: Georgia Medicare Cardiovascular Disease Screening: The Complete Guide subtitle: Section 1861(xx) statutory authority, the NCD 190.23 three-test lipid panel, the once-every-five-years frequency for asymptomatic beneficiaries, the ACA Section 4104 zero-cost-sharing waiver, coordination with the Initial Preventive Physical Examination and Annual Wellness Visit, Intensive Behavioral Therapy for Cardiovascular Disease Risk under NCD 210.11, the Southern Stroke Belt context, the major Georgia cardiovascular centers, and why the Georgia Medicare Cardiovascular Disease Screening benefit matters for every Medicare beneficiary in the state.

For every Georgia Medicare beneficiary asking whether their cholesterol blood test is covered without out-of-pocket cost, every primary care provider ordering screening lipid panels during Annual Wellness Visits or routine preventive encounters, every cardiologist counseling Medicare patients about cardiovascular risk in the Stroke Belt, every laboratory processing Medicare screening specimens in Atlanta, Augusta, Savannah, Columbus, Macon, Albany, and rural Georgia communities, and every Georgia caregiver supporting a family member through cardiovascular risk assessment, the Georgia Medicare Cardiovascular Disease Screening benefit is a no-cost-sharing preventive screening that has been continuously available for over a decade.

By Brevy Care Team · Last verified May 21, 2026

Section 1861(xx) of the Social Security Act

Section 1861(xx) of the Social Security Act, codified at 42 U.S.C. 1395x(xx), defines the cardiovascular disease screening blood tests covered by Medicare. The statute authorizes Medicare to cover cardiovascular disease screening tests for the early detection of cardiovascular disease (or risk for cardiovascular disease). The statute delegates to CMS authority to:

• Define the specific tests covered
• Establish the screening frequency
• Establish coverage conditions
• Update covered tests as evidence evolves

CMS exercises this delegated authority primarily through National Coverage Determination 190.23 Cardiovascular Disease Screening Tests. Section 1861(xx) was added to the Social Security Act by the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA).

Medicare Improvements for Patients and Providers Act of 2008 (MIPPA)

The Medicare Improvements for Patients and Providers Act of 2008 established Medicare coverage of cardiovascular disease screening blood tests by:

• Adding Section 1861(xx) to the Social Security Act
• Authorizing CMS to specify covered tests and frequency
• Providing for screening of asymptomatic beneficiaries
• Coordinating with the broader Medicare preventive services framework

MIPPA was the same legislation that addressed Medicare physician fee schedule issues, established the Medicare Improvement Fund, and made numerous other Medicare program improvements. The cardiovascular disease screening provision took effect in the years following MIPPA's enactment; verify the current implementing parameters in the CMS Medicare Benefit Policy Manual.

National Coverage Determination NCD 190.23

CMS implemented Section 1861(xx) through National Coverage Determination NCD 190.23 Cardiovascular Disease Screening Tests. NCD 190.23 specifies:

• Covered tests: Total cholesterol, HDL cholesterol, and triglycerides (the standard lipid panel)
• Eligible beneficiaries: All Medicare Part B beneficiaries who are asymptomatic for cardiovascular disease
• Frequency: Once every five years
• Specimen requirements: Fasting blood draw (12-hour fast recommended for accurate triglyceride measurement)
• Provider requirements: Order from a treating physician or other qualified non-physician practitioner

NCD 190.23 has remained substantially stable since its implementation, providing predictable coverage for cardiovascular disease screening tests across the Medicare population.

42 CFR 410.17 Implementing Regulations

Implementing regulations at 42 CFR 410.17 address cardiovascular disease screening tests, including:

• Specific covered tests
• Frequency limitations
• Conditions for coverage
• Documentation requirements

The regulation aligns with NCD 190.23 and provides the regulatory foundation for Medicare contractor claim adjudication.

ACA Section 4104 Preventive Services Cost-Sharing Waiver

Section 4104 of the Patient Protection and Affordable Care Act eliminated Medicare beneficiary cost-sharing for certain preventive services. The cost-sharing waiver applies to preventive services rated A or B by the United States Preventive Services Task Force (USPSTF) and to specific Medicare-defined preventive services, including cardiovascular disease screening tests. Section 4104:

• Waived the Part B deductible for covered preventive services
• Waived the standard 20 percent coinsurance for covered preventive services
• Applied to services furnished beginning in the years following enactment

The result is that Medicare beneficiaries pay nothing out-of-pocket for the cardiovascular disease screening lipid panel covered under Section 1861(xx) when furnished by a Medicare-enrolled provider accepting Medicare assignment. This zero-cost-sharing structure removes financial barriers to preventive cardiovascular screening.

The Covered Lipid Panel Under Georgia Medicare Cardiovascular Disease Screening

Three-Test Composition

NCD 190.23 specifies the three tests covered under the cardiovascular disease screening benefit:

Total Cholesterol Total cholesterol measures the sum of all cholesterol carried in the blood, including LDL (often called bad) cholesterol, HDL (often called good) cholesterol, and other cholesterol-containing lipoproteins. Total cholesterol provides an overall picture of blood cholesterol but does not distinguish between cardioprotective HDL and atherogenic LDL. Total cholesterol is measured by CPT 82465.

HDL Cholesterol HDL cholesterol (high-density lipoprotein cholesterol) measures the cardioprotective cholesterol that helps remove other cholesterol from arteries. Higher HDL is generally cardioprotective; lower HDL is a cardiovascular risk factor. HDL cholesterol is measured by CPT 83718.

Triglycerides Triglycerides measure the level of triglyceride fats in the blood. Elevated triglycerides are a cardiovascular risk factor and may indicate metabolic syndrome, diabetes, or other metabolic disorders. Triglycerides are measured by CPT 84478.

CPT 80061 Lipid Panel

Most Medicare cardiovascular disease screening orders use CPT 80061 (Lipid panel), which bundles total cholesterol, HDL cholesterol, and triglycerides into a single laboratory test order. CPT 80061 also typically includes a calculated LDL cholesterol value derived from the other measurements when triglycerides are not severely elevated. The bundled lipid panel is the standard Medicare cardiovascular screening laboratory order.

Fasting Requirements

Accurate triglyceride measurement requires a fasting blood draw, typically 12 hours after the last food or drink intake (water is permitted). Some clinical contexts use non-fasting lipid panels, particularly when only total cholesterol and HDL are of primary interest. Medicare coverage does not require a specific fasting protocol; the clinical decision rests with the ordering provider. Most Georgia Medicare beneficiaries are instructed to schedule morning blood draws after overnight fasting.

Specimen Collection

The screening lipid panel requires a venous blood specimen, typically collected at:

• Primary care provider offices with in-office phlebotomy
• Hospital outpatient laboratories
• Independent laboratory collection sites (Quest Diagnostics, Labcorp)
• Federally Qualified Health Centers (FQHCs)
• Rural Health Clinics (RHCs)
• Community Health Centers

Major commercial laboratories serving Georgia include Quest Diagnostics with patient service centers throughout Georgia, and Labcorp with Georgia collection site coverage. Hospital outpatient laboratories at major Georgia health systems also process screening specimens.

Screening Frequency

Once Every Five Years

Medicare covers cardiovascular disease screening once every five years per beneficiary under NCD 190.23. The frequency limitation:

• Counts from the date of the prior covered screening
• Resets after each covered screening
• Applies regardless of provider, location, or year

A beneficiary screened on March 15, 2026 would be eligible for the next covered screening on or after March 15, 2031. The five-year frequency reflects the relatively slow pace at which lipid profiles change in stable, asymptomatic individuals and the cost-effectiveness considerations of population-wide screening.

What Happens Between Five-Year Intervals

Between covered screening dates, Medicare beneficiaries may have lipid testing under other coverage pathways:

• Diagnostic lipid testing for symptomatic beneficiaries or those with established cardiovascular disease, covered under standard Part B rules with deductible and 20 percent coinsurance
• Lipid testing as part of diabetes monitoring, covered under diabetes management
• Lipid testing for statin therapy monitoring, covered as medically necessary
• Lipid testing under risk-stratified clinical pathways, covered as appropriate

The five-year frequency limitation applies only to the preventive cardiovascular disease screening benefit. Beneficiaries needing more frequent lipid testing for clinical reasons can receive it under diagnostic testing rules.

When the Five-Year Clock Starts

The five-year clock starts at the date of the prior Medicare-covered cardiovascular disease screening. For beneficiaries new to Medicare (e.g., newly age 65), the first eligible screening can occur at any point after Medicare Part B enrollment. The IPPE Welcome to Medicare visit (covered within the first 12 months of Part B enrollment) provides a natural entry point for ordering the screening lipid panel.

Asymptomatic Beneficiary Eligibility for Georgia Medicare Cardiovascular Disease Screening

Asymptomatic Defined

The Medicare cardiovascular disease screening benefit applies only to asymptomatic beneficiaries, meaning beneficiaries without signs, symptoms, or established diagnosis of cardiovascular disease. Asymptomatic generally means:

• No chest pain or angina
• No shortness of breath suggestive of heart disease
• No established diagnosis of coronary artery disease, heart failure, peripheral artery disease, cerebrovascular disease, or other cardiovascular disease
• No prior myocardial infarction or stroke

Beneficiaries with cardiovascular disease symptoms or established diagnosis receive lipid testing as diagnostic testing rather than as preventive screening. The clinical distinction rests with the ordering provider's clinical judgment.

Why Asymptomatic-Only

The asymptomatic-only eligibility reflects the preventive nature of the screening benefit. Preventive screening aims to detect disease or risk factors in apparently healthy individuals before symptoms emerge. Once a beneficiary becomes symptomatic or develops established disease, lipid testing serves a diagnostic, monitoring, or treatment-management purpose rather than a screening purpose.

Clinical Coding Implications

For asymptomatic screening eligible for the Section 1861(xx) benefit, the lipid panel is typically coded with ICD-10 Z13.220 (Encounter for screening for lipoid disorders) or similar Z code. For symptomatic or established-disease testing under diagnostic coverage, the lipid panel is coded with the relevant disease ICD-10 (e.g., E78.0 for hypercholesterolemia, I25.10 for atherosclerotic heart disease).

The ICD-10 coding drives Medicare claim processing distinction between screening (cost-sharing waived) and diagnostic (cost-sharing applies). Provider claim coding accuracy is therefore important to ensure beneficiaries receive the appropriate benefit.

Distinction Between Screening and Diagnostic Testing

Screening Lipid Panel (No Cost-Sharing)

The Section 1861(xx) cardiovascular disease screening benefit applies when:

• The beneficiary is asymptomatic
• The lipid panel is ordered as preventive screening
• The order falls within the once-every-five-years frequency
• The provider codes the encounter with appropriate screening Z codes

Under these conditions, Medicare pays 100 percent of the Medicare-approved amount; the beneficiary pays nothing.

Diagnostic Lipid Panel (Standard Cost-Sharing)

When the lipid panel is ordered for diagnostic, monitoring, or treatment-management purposes, including:

• Evaluation of symptomatic beneficiaries
• Monitoring of established cardiovascular disease
• Statin therapy initiation, dose titration, or response monitoring
• Diabetes-related lipid monitoring
• Familial hypercholesterolemia evaluation
• Evaluation of other diagnosed lipid disorders

The standard Part B coverage applies: Part B deductible applies, and after deductible, beneficiary pays 20 percent coinsurance of the Medicare-approved amount.

Practical Implications

In practice, primary care providers managing Medicare beneficiaries often combine the screening lipid panel (when due under five-year frequency) with broader preventive services during the Annual Wellness Visit. For beneficiaries on statin therapy or with established cardiovascular disease, lipid testing typically occurs more frequently than five years under diagnostic coverage with cost-sharing.

Coordination With the Initial Preventive Physical Examination

Section 1861(ww) IPPE

The Initial Preventive Physical Examination (IPPE), also called the Welcome to Medicare Visit, is codified at Section 1861(ww) of the Social Security Act. The IPPE provides a one-time preventive physical examination available within the first 12 months of Medicare Part B enrollment. The IPPE includes:

• Review of medical and social history with focus on health risk factors
• Review of current opioid prescriptions and screening for substance use disorder
• Measurement of vital signs (height, weight, blood pressure, body mass index)
• Visual acuity screening
• Depression screening
• Cognitive function screening
• End-of-life planning discussion (advance directive education)
• Health education and counseling
• Referrals for needed preventive services

The IPPE is the natural entry point for ordering the Medicare cardiovascular disease screening lipid panel for newly Medicare-enrolled beneficiaries.

IPPE Cardiovascular Risk Assessment

During the IPPE, the provider assesses cardiovascular disease risk factors, including:

• Family history of cardiovascular disease
• Personal history of cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking)
• Lifestyle factors (diet, physical activity, weight)
• Mental health factors that may influence cardiovascular risk
• Other risk factor profile

Based on this assessment, the provider may order the cardiovascular disease screening lipid panel as part of the IPPE-initiated preventive plan.

IPPE Cost-Sharing

The IPPE itself is covered at no beneficiary cost-sharing under the ACA preventive services waiver. The Part B deductible and coinsurance are waived. When the cardiovascular disease screening lipid panel is ordered during or following the IPPE, the lipid panel is also covered at no cost-sharing under the screening benefit. The IPPE therefore provides a single no-cost preventive encounter encompassing comprehensive baseline assessment and cardiovascular screening.

Coordination With the Annual Wellness Visit

Section 1861(hhh) AWV

The Annual Wellness Visit (AWV) is codified at Section 1861(hhh) of the Social Security Act. The AWV provides an annual preventive visit available after the IPPE (or after 12 months of Part B enrollment for beneficiaries who did not receive the IPPE). The AWV includes:

• Establishment of (initial AWV) or update to (subsequent AWVs) personalized prevention plan services
• Health Risk Assessment (HRA)
• Review of medical and family history
• List of current providers and prescriptions
• Vital signs measurement
• Cognitive function screening
• Depression screening
• Functional ability and safety screening
• Personalized health advice and referrals
• Screening schedule for next 5-10 years

AWV Cardiovascular Screening Coordination

The AWV personalized prevention plan typically incorporates cardiovascular disease screening when due under the five-year frequency. During each AWV, the provider:

• Reviews the date of the last covered cardiovascular screening
• Determines whether screening is due
• Orders the lipid panel when due
• Counsels on cardiovascular risk factors
• Coordinates with the broader preventive services portfolio (diabetes screening, colorectal cancer screening, cancer screenings, immunizations)

The AWV thus serves as the recurring annual touchpoint for cardiovascular screening management throughout a beneficiary's Medicare tenure.

AWV and Screening Cost-Sharing

The AWV is covered at no beneficiary cost-sharing under the ACA preventive services waiver. The Part B deductible and coinsurance are waived. When the cardiovascular disease screening lipid panel is ordered during the AWV (or following the AWV with appropriate documentation), the lipid panel is also covered at no cost-sharing. The AWV-plus-screening encounter therefore provides cost-free preventive care for Medicare beneficiaries.

Subsequent AWVs

After the first AWV, beneficiaries are eligible for a subsequent AWV every 12 months. Each subsequent AWV provides an opportunity to:

• Update the personalized prevention plan
• Check whether cardiovascular screening is due
• Order the lipid panel when within the five-year window
• Coordinate broader preventive care

The AWV-driven five-year-rolling cardiovascular screening cycle is the operational backbone of Medicare preventive cardiovascular care.

Coordination With Intensive Behavioral Therapy for Cardiovascular Disease Risk

NCD 210.11 IBT for CVD

National Coverage Determination NCD 210.11 Intensive Behavioral Therapy for Cardiovascular Disease establishes Medicare coverage of intensive behavioral counseling for adults at elevated cardiovascular risk. The benefit:

• Covers one intensive counseling visit per year per beneficiary
• Provides counseling on aspirin use, blood pressure screening, healthy diet, and intensive behavioral counseling
• Must be furnished by a primary care provider in a primary care setting
• Uses HCPCS G0446 (annual face-to-face intensive behavioral therapy for cardiovascular disease, individual)

The IBT for CVD complements the cardiovascular disease screening lipid panel by providing structured counseling and risk reduction interventions in addition to the laboratory screening.

IBT for CVD Cost-Sharing

Like the cardiovascular disease screening benefit, IBT for CVD is covered at no beneficiary cost-sharing under the ACA preventive services waiver. Medicare pays 100 percent of the Medicare-approved amount; the beneficiary pays nothing for the covered annual counseling visit.

When IBT for CVD Is Most Useful

IBT for CVD is most valuable for beneficiaries with elevated cardiovascular risk based on screening results or other risk factor assessment. Following an abnormal screening lipid panel showing elevated LDL or low HDL, a primary care provider can:

• Discuss results with the beneficiary
• Provide IBT for CVD counseling (G0446)
• Recommend lifestyle modification interventions
• Consider statin therapy when appropriate
• Coordinate other preventive interventions

This sequencing, screening followed by counseling and intervention, exemplifies coordinated preventive cardiovascular care in the Medicare framework.

USPSTF Statin Use Recommendation Alignment

USPSTF Recommendation

The USPSTF provides a recommendation in favor of low- to moderate-dose statin therapy for the primary prevention of cardiovascular disease in adults with cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and elevated calculated 10-year cardiovascular disease risk. Consult the current USPSTF recommendation page for the active age band, risk-factor list, and risk threshold.

Implications for Medicare Beneficiaries

While many Medicare beneficiaries are aged 75 or older (beyond the USPSTF primary-prevention age range), the underlying clinical principles of cardiovascular risk reduction inform Medicare preventive care. The cardiovascular disease screening lipid panel provides the data needed to:

• Estimate cardiovascular risk
• Identify beneficiaries who may benefit from statin therapy
• Identify beneficiaries with previously undetected dyslipidemia
• Inform lifestyle counseling and intervention

Statin medications are covered under Medicare Part D for beneficiaries enrolled in Part D plans. Generic statins (atorvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin) are typically available at low cost in Part D plan formularies. The cardiovascular disease screening lipid panel provides the foundation for identifying beneficiaries appropriate for statin consideration.

Service Codes

CPT 80061 Lipid Panel

CPT 80061 represents the comprehensive lipid panel: total cholesterol, HDL cholesterol, and triglycerides as a bundled laboratory test. Most Medicare cardiovascular disease screening orders use CPT 80061 because it captures all three required NCD 190.23 components in a single test. CPT 80061 is also the most common diagnostic lipid testing code; the screening-versus-diagnostic distinction is made through accompanying ICD-10 diagnosis coding.

CPT 82465 Total Cholesterol

CPT 82465 represents total cholesterol measurement (serum) as a standalone test. While most screening orders use the bundled CPT 80061, some providers may order CPT 82465 separately, particularly when only total cholesterol is of clinical interest.

CPT 83718 HDL Cholesterol

CPT 83718 represents HDL cholesterol direct measurement as a standalone test. HDL cholesterol can also be calculated from other lipid measurements; CPT 83718 reflects direct measurement.

CPT 84478 Triglycerides

CPT 84478 represents triglyceride measurement as a standalone test. Triglyceride measurement requires fasting for accurate results.

Standalone Versus Bundled

Most Medicare cardiovascular disease screening encounters use bundled CPT 80061 lipid panel ordering. The bundled approach captures all three NCD 190.23 components in one test order with one laboratory specimen processing. Standalone component testing is less common in routine screening.

Documentation Requirements

Ordering Provider Documentation

The ordering provider must document:

• Asymptomatic status of the beneficiary
• Indication for screening (preventive cardiovascular disease screening)
• Date of last covered screening (to verify five-year frequency)
• Appropriate ICD-10 coding (typically Z13.220 or similar screening Z code)
• Standing or specific order for the lipid panel

Laboratory Documentation

The performing laboratory documents:

• Specimen collection date and time
• Fasting status (if applicable to triglyceride result interpretation)
• Test results with reference ranges
• Quality control compliance
• Ordering provider identification

Claim Documentation

The Medicare claim must:

• Use the appropriate CPT code (80061 or component codes)
• Use the appropriate ICD-10 screening diagnosis code
• Identify the ordering provider
• Reflect the assignment-accepting payment terms

Accurate documentation supports correct claim adjudication as screening (zero cost-sharing) versus diagnostic (cost-sharing applies).

Worked Examples

Example 1: Asymptomatic 67-Year-Old in Macon, Initial Screening Lipid Panel

Mrs. Rodriguez, a 67-year-old Macon resident with no cardiovascular disease symptoms or established diagnosis, visits her primary care provider for her Annual Wellness Visit. During the AWV, the provider reviews her preventive services and notes she has not had a cardiovascular disease screening lipid panel during her Medicare enrollment.

The provider orders CPT 80061 lipid panel with ICD-10 Z13.220 (Encounter for screening for lipoid disorders) at the on-site phlebotomy. The specimen is processed by a commercial laboratory. Results return showing borderline elevated total cholesterol and LDL.

Coverage: The lipid panel is covered under Section 1861(xx) at zero beneficiary cost-sharing because Mrs. Rodriguez is asymptomatic, the screening is within the five-year frequency (first eligible screening), and the order codes the encounter as screening. Mrs. Rodriguez owes nothing for the lipid panel or the AWV during which it was ordered.

Follow-up: The provider discusses the borderline elevated total cholesterol and LDL with Mrs. Rodriguez. The provider provides IBT for CVD counseling (HCPCS G0446) during the same visit at zero cost-sharing. The counseling addresses dietary modification, physical activity, and weight management. The provider sets a follow-up visit in three months to reassess.

Example 2: Five-Year Reset for Prior Screened Beneficiary

Mr. Adams, a 72-year-old Atlanta resident, was last screened with CPT 80061 lipid panel in April 2021. During his April 2026 Annual Wellness Visit, the provider notes the prior screening date.

Eligibility: Mr. Adams is eligible for a new covered cardiovascular disease screening lipid panel approximately five years after the prior covered screening. The April 2026 visit falls within the eligible window.

Order: The provider orders CPT 80061 lipid panel with ICD-10 Z13.220 at the on-site phlebotomy. Specimen processing returns results showing improved lipid values.

Coverage: The lipid panel is covered under Section 1861(xx) at zero cost-sharing. The five-year clock resets to the date of the April 2026 screening; Mr. Adams's next eligible covered screening will be approximately five years later.

Note: Between April 2021 and April 2026, Mr. Adams may have had lipid testing under diagnostic coverage rules if any clinical indication arose. The five-year frequency limitation applies only to the screening benefit, not to medically indicated diagnostic testing.

Example 3: Symptomatic Patient, Diagnostic Testing Pathway Versus Screening

Ms. Carter, a 68-year-old Savannah resident with a recent episode of exertional chest pain, presents for evaluation. The cardiologist orders an evaluation, including a lipid panel as part of the diagnostic cardiovascular workup.

Coverage Pathway: Because Ms. Carter is symptomatic (exertional chest pain), the lipid panel is ordered as diagnostic testing rather than as preventive screening. The order uses ICD-10 R07.9 (Chest pain, unspecified) or other diagnostic codes rather than screening Z codes.

Cost-Sharing: The diagnostic lipid panel is covered under standard Part B rules. Ms. Carter pays the Part B deductible if not already met, and after deductible, 20 percent coinsurance of the Medicare-approved amount.

Implication: The cardiovascular disease screening benefit applies to asymptomatic beneficiaries only. Symptomatic beneficiaries access lipid testing under diagnostic coverage with standard cost-sharing.

Example 4: Coordination With AWV Preventive Plan

Mr. Lee, a 70-year-old Columbus resident, attends his Annual Wellness Visit. The AWV personalized prevention plan addresses:

• Cardiovascular disease screening (CPT 80061 ordered, last screening six years ago, due)
• Colorectal cancer screening (annual FIT test recommended)
• Pneumococcal vaccination (booster due)
• Depression screening (PHQ-2 negative)
• Cognitive screening (Mini-Cog normal)
• Functional ability screening (no concerns)
• IBT for CVD counseling (G0446 discussed during AWV)

Coverage: All listed services are covered at zero beneficiary cost-sharing under the ACA preventive services waiver (AWV, cardiovascular screening, colorectal screening), Medicare Part B preventive vaccine coverage (pneumococcal), and IBT for CVD coverage. Mr. Lee owes nothing for the visit.

Coordination: The AWV serves as the orchestrating visit, with multiple preventive services coordinated in a single encounter. Cardiovascular screening is one component of a broader preventive care portfolio.

Example 5: IBT for CVD G0446 Counseling Following Abnormal Screen

Mrs. Wilson, a 69-year-old Augusta resident, had a screening lipid panel during her AWV showing elevated LDL and low HDL, indicating meaningful cardiovascular risk.

Initial Encounter: At the AWV, the provider orders the lipid panel and identifies the elevated LDL and low HDL on return of results. The provider schedules a follow-up visit specifically for IBT for CVD counseling and treatment planning.

IBT for CVD Visit: At the follow-up visit, the provider delivers IBT for CVD counseling using HCPCS G0446. The counseling addresses:

• Aspirin use considerations (after risk-benefit assessment)
• Blood pressure control
• Healthy diet (Mediterranean, DASH, or similar)
• Physical activity recommendations
• Weight management
• Smoking cessation (if applicable)
• Statin therapy discussion

Coverage: The IBT for CVD visit is covered at zero beneficiary cost-sharing under the ACA preventive services waiver. Mrs. Wilson pays nothing for the counseling visit.

Treatment Plan: The provider initiates moderate-intensity statin therapy. The statin is covered under Mrs. Wilson's Medicare Part D plan formulary at low generic copay. A follow-up lipid panel is scheduled in three months for therapy monitoring; that follow-up will be covered under diagnostic testing (not the five-year screening benefit) because it is monitoring statin response.

Example 6: Rural Southwest Georgia Stroke Belt Beneficiary

Mr. Thompson, a 73-year-old resident of Bainbridge in Decatur County (rural southwest Georgia, part of the deep Stroke Belt), receives care at a Federally Qualified Health Center (FQHC). The FQHC primary care provider conducts his Annual Wellness Visit and notes elevated cardiovascular disease risk given:

• Geographic location in the high-burden Stroke Belt region
• Family history (father had myocardial infarction in late 60s)
• Personal history of borderline hypertension
• Age in the elevated-risk Medicare cohort

Screening Order: The FQHC provider orders CPT 80061 lipid panel with ICD-10 Z13.220 at the FQHC on-site phlebotomy. Specimen processing returns results showing elevated LDL.

Coverage: The screening lipid panel is covered at zero beneficiary cost-sharing under Section 1861(xx) and the ACA preventive services waiver. The FQHC primary care setting fully qualifies for the screening benefit.

Follow-up Care: The provider discusses the elevated LDL and initiates IBT for CVD counseling (G0446) during the same visit. The counseling addresses lifestyle modifications appropriate to rural southwest Georgia context (local food access, walking and physical activity options, smoking cessation resources). A follow-up visit in three months is scheduled to reassess and consider statin therapy.

Rural Access Significance: The Section 1861(xx) cardiovascular disease screening benefit is particularly valuable for Mr. Thompson and other rural southwest Georgia Medicare beneficiaries because:

• The Stroke Belt geographic burden elevates baseline cardiovascular risk
• Local FQHCs and Rural Health Clinics provide accessible primary care entry points
• The zero-cost-sharing structure removes financial barriers in lower-income rural communities
• Coordinated AWV plus screening plus IBT for CVD encounters efficiently use scarce rural primary care capacity

Georgia Cardiovascular Disease Burden and Why Georgia Medicare Cardiovascular Disease Screening Matters

Southern Stroke Belt Context

Georgia sits within the Southern Stroke Belt, a region of southern U.S. states historically documented as having elevated stroke mortality compared to national averages. Within Georgia, the cardiovascular and stroke burden is geographically concentrated in:

• Southwest Georgia (Albany, Bainbridge, Thomasville, Valdosta region)
• Coastal Georgia (Savannah, Brunswick region)
• Central Georgia (Macon, Augusta region in part)
• Rural eastern Georgia

The elevated burden reflects multiple contributing factors, including socioeconomic conditions, food environment, healthcare access, tobacco use prevalence, hypertension prevalence, diabetes prevalence, and historical patterns of health disparities.

Why Cardiovascular Screening Matters for Georgia

The Section 1861(xx) cardiovascular disease screening benefit is particularly important for Georgia Medicare beneficiaries because:

• Higher baseline cardiovascular risk warrants systematic screening
• Many beneficiaries have never had structured cholesterol assessment
• Identification of dyslipidemia enables intervention (statin therapy, lifestyle modification)
• Coordination with diabetes screening, blood pressure management, and smoking cessation creates comprehensive cardiovascular risk reduction
• Zero-cost-sharing removes financial barriers in lower-income communities

Georgia Disease Burden Context

Georgia consistently ranks among states with elevated burden for:

• Stroke mortality
• Cardiovascular disease mortality
• Hypertension prevalence
• Diabetes prevalence
• Obesity prevalence

These elevated burden indicators reinforce the value of the Medicare cardiovascular disease screening benefit for the Georgia Medicare population. Consult the Georgia Department of Public Health and CDC state-level cardiovascular surveillance pages for the current data tables.

Major Georgia Cardiovascular Centers

Emory Heart and Vascular Institute

Emory Heart and Vascular Institute (Atlanta) is an academic cardiovascular center with comprehensive services, including:

• Cardiology consultations
• Electrophysiology
• Interventional cardiology
• Cardiac surgery
• Heart failure care
• Heart transplantation
• Vascular surgery
• Preventive cardiology and lipid management

Emory primary care provides routine cardiovascular disease screening; specialty referrals follow abnormal screening results when appropriate.

Wellstar Heart and Vascular

Wellstar Heart and Vascular provides comprehensive cardiovascular services across the Wellstar Health System's metropolitan Atlanta and north Georgia hospitals. Services include cardiology, electrophysiology, interventional cardiology, cardiac surgery, and preventive cardiology. Wellstar primary care providers throughout the network order routine cardiovascular disease screening.

Piedmont Heart Institute

Piedmont Heart Institute (Atlanta) provides cardiovascular services across the Piedmont Healthcare system. Piedmont Atlanta serves as the academic flagship; Piedmont Newnan, Piedmont Henry, and other system hospitals provide regional cardiovascular care. Piedmont primary care orders routine cardiovascular screening.

Northside Cardiovascular

Northside Cardiovascular provides cardiovascular services through Northside Hospital's metropolitan Atlanta locations. The system includes cardiology, electrophysiology, interventional cardiology, and cardiac surgery. Northside primary care orders routine cardiovascular screening.

Augusta University Heart and Cardiovascular Services

Augusta University Heart and Cardiovascular Services provides academic cardiovascular care for east Georgia. The Augusta University Medical Center provides tertiary cardiovascular services, including cardiac surgery and electrophysiology. Augusta University primary care orders routine cardiovascular screening.

Phoebe Putney Heart Center

Phoebe Putney Heart Center (Albany) provides cardiovascular care for southwest Georgia. Phoebe Putney Memorial Hospital serves as the regional tertiary referral center for the deep Stroke Belt region of southwest Georgia. Phoebe primary care orders routine cardiovascular screening with particular attention to the elevated regional cardiovascular burden.

Memorial Health Cardiovascular

Memorial Health Cardiovascular (Savannah) provides cardiovascular care for coastal Georgia and southeast Georgia. Memorial Health serves as the regional tertiary referral center for coastal Georgia. Memorial primary care orders routine cardiovascular screening.

Other Georgia Cardiovascular Resources

Additional Georgia cardiovascular resources include:

• Grady Health System (Atlanta safety-net)
• St. Joseph's/Candler Heart Hospital (Savannah)
• Houston Healthcare (Warner Robins area)
• University Health System (Augusta region)
• HCA Healthcare Georgia hospitals

Provider Settings for Cardiovascular Disease Screening

Primary Care Provider Offices

Most Medicare cardiovascular disease screening orders originate from primary care provider offices: internal medicine, family medicine, and geriatrics practices. Primary care providers:

• Conduct AWVs incorporating cardiovascular screening
• Order screening lipid panels at on-site phlebotomy or through laboratory referral
• Counsel on cardiovascular risk and intervention
• Coordinate broader preventive care

Primary care is the optimal setting for systematic preventive cardiovascular care for the Medicare population.

Federally Qualified Health Centers (FQHCs)

Federally Qualified Health Centers throughout Georgia provide primary care, including cardiovascular disease screening for Medicare beneficiaries. FQHCs operate under HRSA federal funding and serve underserved communities, including many rural Georgia counties. FQHC services include AWV, cardiovascular screening, and care coordination.

Rural Health Clinics (RHCs)

Rural Health Clinics designated in HRSA Health Professional Shortage Areas or Medically Underserved Areas provide primary care, including cardiovascular disease screening in rural Georgia. RHC services include AWV, cardiovascular screening, and care coordination similar to FQHCs.

Hospital Outpatient Clinics

Hospital outpatient primary care clinics affiliated with major Georgia health systems also provide cardiovascular disease screening for Medicare beneficiaries who receive primary care in these settings.

Independent Laboratory Patient Service Centers

Once a primary care provider orders the screening lipid panel, beneficiaries can have specimen collection at:

• Provider office on-site phlebotomy
• Quest Diagnostics patient service centers throughout Georgia
• Labcorp patient service centers throughout Georgia
• Hospital outpatient laboratory collection sites
• FQHC and RHC on-site phlebotomy

Multiple convenient collection options support accessible screening across urban, suburban, and rural Georgia communities.

Coordination With Other Preventive Screening

Diabetes Screening (Section 1861(yy))

Medicare diabetes screening is codified at Section 1861(yy) of the Social Security Act. The benefit covers diabetes screening tests, including fasting plasma glucose, oral glucose tolerance testing, or HbA1c. The screening benefit is available based on risk factor assessment. Like cardiovascular disease screening, diabetes screening is covered at zero beneficiary cost-sharing under the ACA preventive services waiver.

The cardiovascular disease screening lipid panel and diabetes screening are commonly ordered together because:

• Both address related metabolic and cardiovascular risk
• Both can be obtained from a single fasting blood draw
• Both inform comprehensive cardiometabolic risk assessment
• Both support coordinated preventive care planning

Colorectal Cancer Screening

Medicare colorectal cancer screening is covered under multiple modalities (annual fecal immunochemical test, multi-target stool DNA test, flexible sigmoidoscopy, screening colonoscopy on an interval basis). All modalities are covered at zero cost-sharing under the ACA preventive services waiver. AWVs coordinate colorectal screening with cardiovascular screening as part of comprehensive preventive care.

Cancer Screenings

Other covered Medicare cancer screenings include lung cancer screening (low-dose CT for eligible smokers), breast cancer screening (mammography), cervical cancer screening (Pap test and HPV testing), and prostate cancer screening (PSA testing). All coordinated through AWV preventive planning.

Bone Mass Measurement

Medicare bone mass measurement (DEXA scan for osteoporosis screening) is covered under Section 1861(rr) at zero cost-sharing. AWVs incorporate bone mass measurement consideration for at-risk beneficiaries.

AAA Screening

Medicare abdominal aortic aneurysm (AAA) screening is covered under the applicable NCD for eligible beneficiaries with risk factors. AAA screening complements cardiovascular disease screening as part of comprehensive cardiovascular preventive care.

Diagnostic Testing Pathway

Standard Part B Coverage

When lipid testing is ordered for diagnostic, monitoring, or treatment-management purposes rather than for asymptomatic screening, Medicare Part B covers the testing under standard Part B rules:

• Part B deductible applies (deductible amount adjusted annually)
• After deductible, beneficiary pays 20 percent coinsurance of Medicare-approved amount
• Medicare pays 80 percent of Medicare-approved amount
• Provider must accept assignment for protected pricing

Common Diagnostic Indications

Diagnostic lipid testing indications include:

• Evaluation of chest pain or other cardiovascular symptoms
• Established cardiovascular disease monitoring
• Statin therapy initiation, dose titration, or response monitoring
• Diabetes-related lipid monitoring
• Familial hypercholesterolemia evaluation
• Severe hypertriglyceridemia evaluation
• Pancreatitis evaluation
• Other clinically indicated lipid assessment

Frequency for Diagnostic Testing

Diagnostic lipid testing frequency is determined by clinical necessity rather than by a fixed five-year frequency. Statin therapy patients typically have lipid panels at:

• Therapy initiation baseline
• A few weeks after initiation to assess response
• Months thereafter based on response and stability
• Annually or more frequently for ongoing monitoring

The diagnostic testing pathway provides clinical flexibility for medically necessary lipid testing outside the five-year screening frequency.

Provider Education and Documentation

Provider Awareness

Many primary care providers may not fully utilize the cardiovascular disease screening benefit due to:

• Limited awareness of the five-year frequency
• Confusion about asymptomatic eligibility
• Documentation and coding complexity (screening Z codes vs diagnostic ICD-10)
• Workflow integration challenges
• Time constraints in primary care encounters

Provider education and EMR-embedded reminder systems can improve appropriate utilization of the screening benefit.

Documentation Best Practices

Best documentation practices include:

• Documenting asymptomatic status in the encounter note
• Documenting date of last covered screening
• Using appropriate screening ICD-10 codes (Z13.220 or similar)
• Ordering CPT 80061 lipid panel
• Documenting AWV or IPPE context if applicable
• Documenting follow-up plan based on results

Provider Best Practices

Best provider practices for cardiovascular screening include:

1. Systematic AWV implementation: Use AWVs as the recurring touchpoint for screening management
2. Five-year clock tracking: EMR-based tracking of last screening date and next eligible date
3. Bundled fasting orders: Coordinate cardiovascular screening with diabetes screening for efficient single-fast specimen collection
4. Coding accuracy: Use appropriate screening Z codes to ensure correct claim adjudication
5. Result-based intervention: Coordinate IBT for CVD G0446 counseling following abnormal results
6. Statin consideration: Discuss statin therapy for appropriate elevated-risk patients
7. Care coordination: Coordinate with cardiology specialty referral when appropriate
8. Lifestyle counseling: Provide diet, physical activity, and smoking cessation counseling
9. Family history documentation: Capture family cardiovascular history for risk stratification
10. Diabetes screening coordination: Pair cardiovascular and diabetes screening
11. Beneficiary education: Explain the zero-cost-sharing structure to remove perceived barriers
12. Follow-up tracking: Ensure abnormal results lead to appropriate follow-up
13. EMR templates: Use standardized screening order templates for consistency
14. Quality measure alignment: Coordinate with cardiovascular quality measures

Common Issues and Resolutions

1. Beneficiary charged cost-sharing for covered screening: Occurs when claim is coded with diagnostic ICD-10 rather than screening Z code. Resolution: provider claim correction with appropriate Z code.
2. Screening ordered too soon (within five years): Frequency violation results in claim denial. Resolution: verify last screening date before ordering; if clinically necessary, order under diagnostic testing rules.
3. Symptomatic patient screening misclassification: Symptomatic patients cannot receive the screening benefit. Resolution: order under diagnostic coverage with appropriate ICD-10 coding.
4. Provider unaware of zero cost-sharing: Some providers incorrectly counsel beneficiaries about cost-sharing for screening. Resolution: provider education on the ACA preventive services waiver.
5. Beneficiary doesn't fast adequately: Inadequate fasting affects triglyceride accuracy. Resolution: clear pre-test instructions for fasting; reschedule if needed.
6. EMR doesn't flag five-year eligibility: Without EMR support, providers may miss screening opportunities. Resolution: implement EMR reminder systems for cardiovascular screening eligibility.
7. Confusion with diagnostic lipid testing frequency: Five-year frequency applies to screening only. Resolution: clarify diagnostic versus screening coding and pathway.
8. Missing AWV coordination: Cardiovascular screening is most efficiently coordinated through the AWV. Resolution: integrate screening into AWV workflows.
9. Specimen collection logistics: Beneficiary may not have transportation to specimen collection. Resolution: use on-site phlebotomy, mobile phlebotomy services, or local FQHC and RHC collection.
10. Provider missing IBT for CVD opportunity: Abnormal screening results warrant IBT for CVD counseling. Resolution: implement workflow to schedule G0446 follow-up after abnormal screening.
11. Beneficiary refuses screening due to perceived complexity: Counseling about no cost-sharing and minimal test burden can address. Resolution: clear beneficiary education.
12. Lab uses outdated CPT codes: Coding errors result in claim issues. Resolution: laboratory billing accuracy oversight.
13. Rural beneficiary access barriers: Specimen collection access can be limited rurally. Resolution: use RHC, FQHC, mobile phlebotomy, or pharmacy-based collection.
14. Beneficiary already had recent commercial insurance lipid test: Recent prior testing under different coverage doesn't affect Medicare five-year eligibility. Resolution: order under the Medicare benefit when the eligibility window opens.

A few more common questions:

Do I need a doctor's order? Yes, the screening lipid panel requires an order from a treating physician or other qualified non-physician practitioner. Primary care providers typically order the screening during the AWV, IPPE, or routine preventive encounters.

What ICD-10 codes apply? The typical screening ICD-10 code is Z13.220 (Encounter for screening for lipoid disorders). The use of screening Z codes (rather than diagnostic ICD-10 codes) is what triggers Medicare claim processing under the screening benefit with zero cost-sharing.

What if I had a non-Medicare lipid test recently? Prior lipid testing under non-Medicare coverage (commercial insurance, self-pay) doesn't affect Medicare five-year eligibility. The five-year clock counts only Medicare-covered cardiovascular disease screening tests.

What if I'm in Medicare Advantage (Part C)? Medicare Advantage plans must cover the same preventive services as Original Medicare at zero cost-sharing for in-network providers. Medicare Advantage beneficiaries access cardiovascular disease screening through their plan's network providers under the same Section 1861(xx) framework.

Are statins covered? Yes, statin medications are covered under Medicare Part D for beneficiaries enrolled in Part D plans. Generic statins (atorvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin) are typically available at low cost in Part D plan formularies.